PDE5A and pulmonary arterial hypertension: At the present time, the orally administrated PDE5 inhibitors sildenafil and tadalafil have Food and Drug Administration approval for the treatment of ED as well as pulmonary arterial hypertension (PAH); whereas vardenafil and avanafil are approved only for ED.